NCT06206629

Brief Summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting both upper and lower motor neurons. Electroneuromyography is an important tool for the diagnosis. Previous studies have shown that different components of the blink reflex, such as the latencies of homo- and contralateral R2 responses can be affected. Studies have found that a contralateral R1 component can appear in neurological diseases with affection of the central nervous system especially upper motor neuron, such as HTLV1 infection. Thus, you aim to determine if a contralateral R1 component could be present in ALS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 4, 2024

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 16, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

February 15, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 5, 2024

Completed
Last Updated

October 9, 2024

Status Verified

October 1, 2024

Enrollment Period

7 months

First QC Date

January 4, 2024

Last Update Submit

October 8, 2024

Conditions

Keywords

Amyotrophic lateral sclerosisALSElectroneuromyographyENMG

Outcome Measures

Primary Outcomes (1)

  • Presence of a contralateral R1 component on blink reflex evaluation.

    A blink reflex evaluation will be performed in all subjects : Blink reflex will be recorded with surface electrodes placed medially over the lower part of the eyelid, on the orbicularis oculi muscle, with a reference electrode 2 cm laterally. Stimuli will be delivered to the supraorbital nerve by surface electrodes with an intensity required to generate a consistent homolateral R1 response. A contralateral R1 component will be defined as an early compound muscle action potential recorded in the contralateral orbicularis oculi muscle.

    Day 1

Study Arms (3)

ALS patients

Patients with ALS (Awaji criteria)

Diagnostic Test: blink reflex evaluation

Non-ALS patients

Patients referred to the neurophysiology unit for a suspicion of ALS du to motor weakness, but in whom the diagnosis is ruled out.

Diagnostic Test: blink reflex evaluation

Healthy volunteers

Healthy volunteers who will undergo a blink reflex evaluation on ENMG.

Diagnostic Test: blink reflex evaluation

Interventions

A blink reflex evaluation will be performed in all subjects

ALS patientsHealthy volunteersNon-ALS patients

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients referred to the neurophysiology unit from the Hospices civils de Lyon, for a suspicion of motor neuron disease. And healthy volunteers for the third group.

You may qualify if:

  • For patients
  • Aged 18 to 99 years old
  • Referred for suspected motor neuromuscular disease
  • Collection of non-opposition
  • For healthy subjects:
  • Aged 18 to 99 years old
  • Absence of any neurological pathology
  • Collection of non-opposition

You may not qualify if:

  • Previous damage linked to another cause of the cranial nerves
  • Prior brainstem lesions
  • Persons deprived of liberty by a judicial or administrative decision
  • Patient under judicial protection, unable to express consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital neurologique Pierre Wertheimer

Bron, Rhone, 69500, France

Location

CHU de Nantes

Nantes, 44093, France

Location

MeSH Terms

Conditions

Amyotrophic Lateral Sclerosis

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesMotor Neuron DiseaseNeurodegenerative DiseasesTDP-43 ProteinopathiesNeuromuscular DiseasesProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2024

First Posted

January 16, 2024

Study Start

February 15, 2024

Primary Completion

September 5, 2024

Study Completion

September 5, 2024

Last Updated

October 9, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations